In 1998, Clay B. Siegall co-founded Seattle Genetics. Clay emphasizes on the importance of alternative cancer treatments, which explains why he established the company. Clay’s objective is to develop therapy treatment for cancer patients. Dr. Clay’s leadership skills and dedication has seen Seattle Genetics enter into multiple licenses and partnerships with companies like Abbvie, Pfizer, and Genentech. In fact, the licenses have generated over $350 million for Seattle Genetics since it received the FDA approval to date. Additionally, Clay has secured over $1.2 billion through capital-raising activities, such as public and private financings including the IPO in 2001.
Clay Siegall was working with Bristol-Myers Squibb Pharmaceutical before co-establishing Seattle Genetics. He worked with the institute from 1991 to 1997. Clay also worked for the National Institutes of Health and National Cancer Institute. Additionally, the scientist serves on boards of various companies, such as the Washington Roundtable, Directors of Ultragenyx Pharmaceutical and Alder Biopharmaceuticals. Siegall has received several awards, thanks to his hard work and dedication in the medical field, including Math and Natural Sciences and University of Maryland Alumnus of the year in 2013. Besides his medical career, Clay is a holder of 15 patents and an author of over 70 publications.
Most people will admit that the success of Seattle Genetics surprises them, and they wouldn’t mind knowing the secret. In that spirit, Clay reveals that collaborating with other players in the medical industry has played a significant role in making the biotech firm successful. Seattle Genetics works with innovators and leaders in oncology drug development. Consequently, the company’s ADC collaborators extended the reach of its technology, which allowed Seattle Genetics to place new approaches and ideas to assist patients.
According to Clay Siegall, the primary objective of Seattle Genetics is to help patients. He developed that passion after watching his father suffer during his cancer treatment. He has an aim of treating cancer patients in a better and more efficient way than before to reduce the pain that these patients go through during chemotherapy treatment. In fact, Clay admits that waking up each day to go to work has been exciting him for the last three decades.